Thioureas

ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting

Retrieved on: 
Saturday, April 10, 2021
Nonsteroidal antiandrogens, Chemistry, Organic compounds, Chemical compounds, Prostate cancer, Benzamides, Nitriles, Thioureas, Enzalutamide, Androgen receptor, Antiandrogen, EPI-7386

In the cellular model CWR-R1-AD1, driven by full-length AR, EPI-7386 inhibited the transcriptional activity of the AR similar to enzalutamide.

Key Points: 
  • In the cellular model CWR-R1-AD1, driven by full-length AR, EPI-7386 inhibited the transcriptional activity of the AR similar to enzalutamide.
  • The AR-v567es splice variant is a clinically-detected AR splice variant that is constitutively active and is unresponsive to anti-androgens.
  • Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018).
  • ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Organic compounds, Chemical compounds, Chemistry, Astellas Pharma, Enzalutamide, Progonadotropins, Prostate cancer, Thioureas, Cancer research, Origin of replication, American Association for Cancer Research, Cancer

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.
  • We look forward to the continued advancements of these programs and our discovery research pipeline as we work to improve the lives of patients with cancer.
  • It has previously been demonstrated that ORIC-101 reverses GR-mediated resistance to enzalutamide and to AR degraders in preclinical prostate cancer cell lines.
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

Retrieved on: 
Monday, December 21, 2020
Organic compounds, Carbonyl compounds, Chemical compounds, Benzamides, Nitriles, Nonsteroidal antiandrogens, Orphan drugs, Enzalutamide, Thioureas, Paclitaxel, Protein-bound paclitaxel, Prostate cancer

I am grateful to the patients and their families, investigators, and our employees who have helped us reach this important milestone.

Key Points: 
  • I am grateful to the patients and their families, investigators, and our employees who have helped us reach this important milestone.
  • The Phase 1b clinical study of ORIC-101 in combination with enzalutamide is a non-randomized, multicenter, open-label study to establish the RP2D, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity when administered to patients with metastatic prostate cancer.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.
  • Such forward-looking statements include, among other things, progress related to ORICs Phase 1b clinical study of ORIC-101 with Abraxane (nab-paclitaxel), including expectations related to initiation of expansion cohorts and patient enrollment.

Global Prostate Cancer Disease Forecast and Market Analysis 2020-2036: Prescribing of Next-Generation Hormone Therapies in Earlier Treatment Settings will Drive Growth of the Market

Retrieved on: 
Friday, December 18, 2020
Organic compounds, Prostate cancer, Chemical compounds, Anatomy, Nonsteroidal antiandrogens, Progonadotropins, Nitriles, Enzalutamide, Thioureas, MCRPC, Prostate, Cabazitaxel

Prostate cancer drugs, on average, take 9.0 years from Phase I to approval, compared to 9.5 years in the overall oncology space.

Key Points: 
  • Prostate cancer drugs, on average, take 9.0 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
  • Pfizer's next-generation androgen receptor (AR) inhibitor Xtandi is the market leader in prostate cancer due to its established efficacy across prostate cancer segmentations and a lack of near-term generic competition.
  • Bolstered by recent and planned expansions into additional prostate cancer segments, Xtandi will continue to be the leading option in this indication.
  • Future expansion opportunities include potential use in combination with PARP inhibitors Talzenna or Rubraca in metastatic castration-resistant prostate cancer (mCRPC) patients.

Signs of Healthy Aging Found in Ergothioneine Telomere Study

Retrieved on: 
Thursday, December 10, 2020
Branches of biology, Biology, Ergothioneine, Imidazolines, Thioureas, Telomere, Ageing

RANCHO SANTA MARGARITA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- An in vitro study published in the Journal of Dietary Supplements , demonstrated Blue Californias ErgoActive ergothioneine helped to preserve telomere length and reduced the rate of telomere shortening under oxidative stress.

Key Points: 
  • RANCHO SANTA MARGARITA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- An in vitro study published in the Journal of Dietary Supplements , demonstrated Blue Californias ErgoActive ergothioneine helped to preserve telomere length and reduced the rate of telomere shortening under oxidative stress.
  • The in vitro study is the first time ergothioneine has been studied for its effect on telomere length.
  • Blue California provided its ErgoActive ergothioneine, which is produced by a proprietary fermentation process.
  • Our results suggest that ergothioneine as part of a healthy diet could potentially mitigate the negative effects of oxidative stress and support healthy aging by helping to preserve telomere length and reduce the rate of shortening, said Chief Science Officer, Dr. Priscilla Samuel.

LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial

Retrieved on: 
Sunday, September 20, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organic compounds, Hormones, Chemical compounds, Prostate cancer, RTT, Nonsteroidal antiandrogens, Progonadotropins, Enzalutamide, Thioureas, Cytopenia, Chemotherapy, Pulmonary embolism, PROfound, LYNPARZA® (olaparib), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Repair (HRR) Mutations, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1).

Key Points: 
  • Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1).
  • Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment.
  • Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm.
  • Patients receiving LYNPARZA and ADT had a 6% incidence of pulmonary embolism compared to 0.8% of patients treated with ADT plus either enzalutamide or abiraterone.

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

Retrieved on: 
Monday, July 27, 2020
Organic compounds, Chemical compounds, Prostate cancer, Hormones, RTT, Nonsteroidal antiandrogens, Progonadotropins, Thioureas, Enzalutamide, Management of prostate cancer, Abiraterone acetate, James L. Gulley

VERU-111 is a novel, oral, first-in-class, tubulin targeting agent that crosslinks and disrupts alpha and beta tubulin subunits of microtubules.

Key Points: 
  • VERU-111 is a novel, oral, first-in-class, tubulin targeting agent that crosslinks and disrupts alpha and beta tubulin subunits of microtubules.
  • VERU-111 is in clinical development to treat metastatic castration and novel androgen receptor targeting agent (enzalutamide or abiraterone) resistant prostate cancer, a growing unmet medical need in advanced prostate cancer.
  • Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer.
  • VERU-111 is being evaluated in an open label Phase 1b/Phase 2 clinical study in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer.

Blue California Files Patent on the Use of Ergothioneine as a Support for Oxidative Stress Related Health Conditions, including COVID-19

Retrieved on: 
Tuesday, July 14, 2020
Branches of biology, Biology, Senescence, Ergothioneine, Imidazolines, Thioureas, Oxidative stress, Telomere

This follows Blue Californias Feb. 2020 patent application reporting the discovery that Ergothioneine inhibits the shortening of telomeres typically associated with oxidative stress.

Key Points: 
  • This follows Blue Californias Feb. 2020 patent application reporting the discovery that Ergothioneine inhibits the shortening of telomeres typically associated with oxidative stress.
  • Specifically, it claims that Ergothioneine can mitigate oxidative stress triggering the inflammatory response in many chronic conditions associated with heart disease, diabetes and cancer.
  • Also, in support of other oxidative conditions associated with oxidative stress including COVID-19 as well as other viral diseases.
  • We will be studying how Ergothioneine supplementation can support various health benefits, including immune health.

LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone

Retrieved on: 
Wednesday, May 20, 2020
Oncology, Health, FDA, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Hormones, RTT, Nonsteroidal antiandrogens, Progonadotropins, Thioureas, Enzalutamide, Prostate cancer, MCRPC, Cancer, Abiraterone, PROfound, LYNPARZA® (olaparib), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Repair (HRR) Mutations, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

Patients receiving LYNPARZA and ADT had a 6% incidence of pulmonary embolism compared to 0.8% of patients treated with ADT plus either enzalutamide or abiraterone.

Key Points: 
  • Patients receiving LYNPARZA and ADT had a 6% incidence of pulmonary embolism compared to 0.8% of patients treated with ADT plus either enzalutamide or abiraterone.
  • Dave Fredrickson, executive vice president, head of the oncology business unit, AstraZeneca, said, Today marks the first approval for LYNPARZA in prostate cancer.
  • LYNPARZA is currently under regulatory review in the European Union and other jurisdictions as a treatment for men with HRR gene-mutated mCRPC.
  • For the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.

Significant Improvement in Overall Survival with ERLEADA®▼ (apalutamide) for Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Thursday, May 14, 2020
Oncology, Health, Clinical trials, Research, Pharmaceutical, Science, Chemical compounds, Organic compounds, Chemistry, Nonsteroidal antiandrogens, Progonadotropins, Lactams, Thioureas, Apalutamide, Prostate cancer, Enzalutamide, Management of prostate cancer

Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results from the Phase 3 SPARTAN Study.

Key Points: 
  • Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results from the Phase 3 SPARTAN Study.
  • Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results from the Phase 3 SPARTAN Study.
  • Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.